Pfizer (PFE) Reports Positive Phase 3 Trial Results for Elrexfio in Multiple Myeloma

gurufocus.com · 2026-10-27

On October 27, 2026, Pfizer Inc (NYSE: PFE) announced successful results from its Phase 3 MagnetisMM-32 trial evaluating Elrexfio (elranatamab), a novel therapy

TickrTrends take: Pfizer's positive Phase 3 trial results for Elrexfio represent a potential revenue driver for the company's oncology pipeline, though TickrTrends currently derives an Overvalued verdict for PFE. Investors focused on valuation metrics should monitor whether this clinical success translates into meaningful earnings accretion relative to the company's current market price in the Healthcare sector. The market's reaction to this trial data and any subsequent regulatory progress will be important to track against PFE's present valuation standing.

Read the full story at gurufocus.com →